Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Cindy Spittle"'
Autor:
Jessica Kristof, Kellen Sakrison, Xiaoping Jin, Kenji Nakamaru, Matthias Schneider, Robert A Beckman, Daniel Freeman, Cindy Spittle, Wenqin Feng
Publikováno v:
Biomarker Insights, Vol 12 (2017)
In preclinical studies, heregulin ( HRG ) expression was shown to be the most relevant predictive biomarker for response to patritumab, a fully human anti–epidermal growth factor receptor 3 monoclonal antibody. In support of a phase 2 study of erlo
Externí odkaz:
https://doaj.org/article/d370f46b4155425ea8597a761feb80d1
Publikováno v:
Cancer Research. 80:896-896
Introduction: Chimeric antigen receptor T (CAR T) cells are an important emerging therapy for hematologic malignancies and are currently being investigated for other cancer types as well. CAR-T cells require a retrovirus or lentivirus to introduce th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::188260e1c7c2b5af47e491de2b46e8c3
https://doi.org/10.1158/1538-7445.am2020-896
https://doi.org/10.1158/1538-7445.am2020-896
Autor:
David Polsky, Iman Osman, Mahrukh M. Syeda, Cindy Spittle, Broderick Corless, George Karlin-Neumann
Publikováno v:
Clinical Cancer Research. 26:A66-A66
Introduction: Serial monitoring of sensitive and specific blood-based biomarkers of disease burden in cancer patients could enable clinicians to adjust treatments at the earliest signs of disease progression when the likelihood of improved outcomes i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::28caf7776301299347210e00143dc1bf
https://doi.org/10.1158/1557-3265.liqbiop20-a66
https://doi.org/10.1158/1557-3265.liqbiop20-a66
Autor:
Gregory Chang, Nathaniel H. Fleming, Yongzhao Shao, Cindy Spittle, Farbod Darvishian, Russell S. Berman, Iman Osman, Mahrukh M. Syeda, George Karlin-Neumann, Anna C. Pavlick, Richard L. Shapiro, Jyothirmayee S. Tadepalli, Shria Blake, Jennifer M. Wiggins, Broderick Corless, David Polsky
Publikováno v:
The Journal of investigative dermatology. 140(8)
Mutational heterogeneity can contribute to therapeutic resistance in solid cancers. In melanoma, the frequencies of intertumoral and intratumoral heterogeneity are controversial. We examined mutational heterogeneity within individual patients with me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::abf05a077368078f0cb38abec6a45c80
https://pubmed.ncbi.nlm.nih.gov/32709275
https://pubmed.ncbi.nlm.nih.gov/32709275
Autor:
Mahrukh M, Syeda, Jennifer M, Wiggins, Broderick, Corless, Cindy, Spittle, George, Karlin-Neumann, David, Polsky
Publikováno v:
Methods in molecular biology (Clifton, N.J.). 2055
The detection of cell-free, circulating tumor DNA (ctDNA) in the blood of patients with solid tumors is often referred to as "liquid biopsy." ctDNA is particularly attractive as a candidate biomarker in the blood. It is relatively stable after blood
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2eba1275bb545381e2b8481a19a537a9
https://pubmed.ncbi.nlm.nih.gov/31502151
https://pubmed.ncbi.nlm.nih.gov/31502151
Autor:
Broderick Corless, Mahrukh M. Syeda, David Polsky, Cindy Spittle, Jennifer M. Wiggins, George Karlin-Neumann
Publikováno v:
Biomarkers for Immunotherapy of Cancer ISBN: 9781493997725
The detection of cell-free, circulating tumor DNA (ctDNA) in the blood of patients with solid tumors is often referred to as "liquid biopsy." ctDNA is particularly attractive as a candidate biomarker in the blood. It is relatively stable after blood
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e580935cc149d7efbab0c607074f56ec
https://doi.org/10.1007/978-1-4939-9773-2_7
https://doi.org/10.1007/978-1-4939-9773-2_7
Autor:
Richard L. Shapiro, George Karlin-Neumann, Gregory Chang, Cindy Spittle, Farbod Darvishian, Iman Osman, Broderick Corless, Anna C. Pavlick, Nathaniel H. Fleming, Russell S. Berman, David Polsky
Publikováno v:
Cancer Research. 79:4704-4704
Purpose: The mutational spectra of melanoma has been well characterized; however, the presence of distinct subclones among multiple tumors from a given patient has been less well described. As mutational heterogeneity has been associated with decreas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d97d7354b48998f1d2a4400ff4e24b64
https://doi.org/10.1158/1538-7445.am2019-4704
https://doi.org/10.1158/1538-7445.am2019-4704
Autor:
Dawne N. Shelton, Jyothirmayee S. Tadepalli, Manohar R. Furtado, Yilong Zhang, Anna C. Pavlick, Sarah A. Weiss, Eric Robinson, Iman Osman, George Karlin-Neumann, David Polsky, Yongzhao Shao, Cindy Spittle, Gregory Chang
Publikováno v:
Molecular Oncology. 10:157-165
Melanoma lacks a clinically useful blood-based biomarker of disease activity to help guide patient management. To determine whether measurements of circulating, cell-free, tumor-associated BRAF(mutant) and NRAS(mutant) DNA (ctDNA) have a higher sensi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb83ffbbdecee8cfc0615fe217cc0705
https://doi.org/10.1016/j.molonc.2015.09.005
https://doi.org/10.1016/j.molonc.2015.09.005
Autor:
Xiaodong Wang, Weihua Liu, Zhenyu Yan, Cindy Spittle, Chad Galderisi, Jin Li, Peng Fang, Scott Glynn, Jennifer Biroschak
Publikováno v:
Cancer Research. 78:4522-4522
FLT3 ITD, a prognostic marker and drug target, is present in ~19% of AML patients. FLT3 ITD is a tandem repeat of the entire or partial exon 13-15 region. FLT3 ITDs range in size from 3bp to above 300bp and impact RTK signaling. Recent publications h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3a5a7819ff6490fc2d5271c12ea4d110
https://doi.org/10.1158/1538-7445.am2018-4522
https://doi.org/10.1158/1538-7445.am2018-4522
Autor:
Andre Marziali, Anna C. Pavlick, Greg Chang, Matthew Wiggin, David Polsky, Jin Li, Iman Osman, Laura Mai, Weihua Liu, Cindy Spittle, Melissa A. Wilson, Broderick Corless, George Karlin-Neumann
Publikováno v:
Cancer Research. 78:5531-5531
Purpose Melanoma patients with BRAFmutant tumors often develop resistance to BRAF-inhibitor therapies. Co-occurring mutations, present at the time of treatment initiation, have been identified in patients with primary treatment resistance, and NRAS m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c4c22eb6843b5753dd9c7c13eb9e180a
https://doi.org/10.1158/1538-7445.am2018-5531
https://doi.org/10.1158/1538-7445.am2018-5531